BioTech
-
Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer
CHICAGO — Delfi Diagnostics, a company seeking to develop liquid biopsy tests to help screen for lung cancer, published a…
Read More » -
Readout Newsletter: Enhertu, AstraZeneca, Agios, GSK
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your…
Read More » -
Structure Therapeutics oral GLP-1 drug led to weight loss in two studies
Structure Therapeutics reported Monday that its oral GLP-1 drug led to weight loss in two studies, leading shares to surge…
Read More » -
Beta-thalassemia drug from Agios hits goal in Phase 3 study
Agios Pharmaceuticals said Monday that its drug called mitapivat reduced the need for blood transfusions in patients with a severe…
Read More » -
AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?
CHICAGO — AstraZeneca’s head of cancer research and development, Susan Galbraith, is British, and prone to a particularly British style…
Read More » -
Intellia reports positive results for its CRISPR-based treatment
Intellia Therapeutics said Saturday that the first 10 patients to receive a CRISPR-based treatment for hereditary angioedema, a genetic disease,…
Read More » -
At ASCO, Astra Zeneca reports strong data for breast cancer drug
CHICAGO — The cancer drug Enhertu stalled the growth of tumors by more than a year, significantly longer than standard…
Read More » -
ASCO Daily Recap: Safety data for Novartis myelofibrosis candidate, survival data for Pfizer drug
You’re reading the web edition of ASCO in 30 Seconds, STAT’s guide to the American Society of Clinical Oncology annual…
Read More » -
FDA’s Pazdur wants cancer trials to range beyond China alone
CHICAGO — The Food and Drug Administration’s top oncologist reiterated that the agency doesn’t want drugmakers applying for approval with data…
Read More » -
Corbus shows ‘reassuring’ data on ADC bladder cancer treatment
CHICAGO — Corbus Pharmaceuticals is the second best-performing biotech stock this year, thanks to investor interest in an antibody-drug conjugate…
Read More »